AR092993A1 - Laquinimod para reducir el daño talamico en la esclerosis multiple - Google Patents
Laquinimod para reducir el daño talamico en la esclerosis multipleInfo
- Publication number
- AR092993A1 AR092993A1 ARP130103705A ARP130103705A AR092993A1 AR 092993 A1 AR092993 A1 AR 092993A1 AR P130103705 A ARP130103705 A AR P130103705A AR P130103705 A ARP130103705 A AR P130103705A AR 092993 A1 AR092993 A1 AR 092993A1
- Authority
- AR
- Argentina
- Prior art keywords
- laquinimod
- subject
- multiple sclerosis
- damage
- affected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Abstract
Método para inhibir o reducir el daño talámico en un sujeto que comprende administrarle al sujeto una cantidad de laquinimod, en donde el sujeto es un paciente humano afectado por una forma de esclerosis múltiple o que presenta un síndrome clínicamente aislado al que se le ha determinado que tiene daño talámico en condiciones basales, un sujeto afectado por una enfermedad o trastorno diferente de una forma de esclerosis múltiple o un síndrome clínicamente aislado, o un sujeto que no está afectado por una forma de esclerosis múltiple ni presenta un síndrome clínicamente aislado, y laquinimod y composiciones farmacéuticas de laquinimod para uso del mismo. Métodos para inhibir o reducir el tremor o espasticidad en un sujeto afectado por tremor o espasticidad, que comprende administrarle al sujeto una cantidad de laquinimod, y laquinimod y composiciones farmacéuticas de laquinimod para uso del mismo. Reivindicación 51: Laquinimod caracterizado porque es para usar en la inhibición o reducción del daño talámico en un paciente humano al que se le ha determinado que tiene daño talámico en condiciones basales. Reivindicación 52: Una composición farmacéutica caracterizada porque comprende una cantidad de laquinimod para usar en la inhibición o reducción del daño talámico en un paciente humano al que se le ha determinado que tiene daño talámico en condiciones basales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261713256P | 2012-10-12 | 2012-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092993A1 true AR092993A1 (es) | 2015-05-13 |
Family
ID=50475887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103705A AR092993A1 (es) | 2012-10-12 | 2013-10-11 | Laquinimod para reducir el daño talamico en la esclerosis multiple |
Country Status (18)
Country | Link |
---|---|
US (2) | US20140107154A1 (es) |
EP (1) | EP2961406A4 (es) |
JP (1) | JP2015533163A (es) |
KR (1) | KR20150080509A (es) |
CN (1) | CN105263325A (es) |
AR (1) | AR092993A1 (es) |
AU (2) | AU2013329348A1 (es) |
BR (1) | BR112015007782A2 (es) |
CA (1) | CA2884272A1 (es) |
CL (2) | CL2015000732A1 (es) |
EA (1) | EA201590726A1 (es) |
HK (1) | HK1218865A1 (es) |
IL (1) | IL237745A0 (es) |
MX (1) | MX2015004564A (es) |
PE (1) | PE20151435A1 (es) |
SG (1) | SG11201501874TA (es) |
TW (1) | TW201420101A (es) |
WO (1) | WO2014058979A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
WO2013123419A1 (en) | 2012-02-16 | 2013-08-22 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
CA2900503A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
TW201609098A (zh) * | 2013-12-20 | 2016-03-16 | 泰瓦藥品工業有限公司 | 拉喹莫德(laquinimod)於延緩亨丁頓舞蹈症進展的用途 |
AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
US20190224186A1 (en) * | 2016-09-13 | 2019-07-25 | Intekrin Therapeutics, Inc. | Treatment of multiple sclerosis with chs-131 |
CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性***PPARγ激动剂 |
CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006076681A2 (en) * | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
RU2009105179A (ru) * | 2006-07-17 | 2010-08-27 | Новартис АГ (CH) | Сульфониламинокарбонилпроизводные амидов холевой кислоты для применения в качестве иммуномодуляторов |
TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
BR112012000568A2 (pt) * | 2009-06-19 | 2015-10-06 | Teva Pharma | tratamento da esclerose múltipla com laquinimod |
PL2467372T3 (pl) * | 2009-08-10 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu |
EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
MX2013006464A (es) * | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
EP2691393B1 (en) * | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
MX2014004420A (es) * | 2011-10-12 | 2014-07-09 | Teva Pharma | Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod. |
TW201804997A (zh) * | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en active Application Filing
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Application Discontinuation
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-15 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20150080509A (ko) | 2015-07-09 |
MX2015004564A (es) | 2015-07-21 |
EA201590726A1 (ru) | 2015-10-30 |
IL237745A0 (en) | 2015-05-31 |
BR112015007782A2 (pt) | 2017-07-04 |
CL2015000732A1 (es) | 2015-08-07 |
CA2884272A1 (en) | 2014-04-17 |
AU2013329348A1 (en) | 2015-05-28 |
CN105263325A8 (zh) | 2017-07-14 |
AU2017203896A1 (en) | 2017-06-29 |
EP2961406A2 (en) | 2016-01-06 |
WO2014058979A3 (en) | 2015-08-20 |
HK1218865A1 (zh) | 2017-03-17 |
US20160296511A1 (en) | 2016-10-13 |
JP2015533163A (ja) | 2015-11-19 |
CN105263325A (zh) | 2016-01-20 |
SG11201501874TA (en) | 2015-05-28 |
PE20151435A1 (es) | 2015-10-15 |
EP2961406A4 (en) | 2017-01-04 |
WO2014058979A8 (en) | 2015-04-16 |
CL2016002873A1 (es) | 2017-04-17 |
US20140107154A1 (en) | 2014-04-17 |
WO2014058979A2 (en) | 2014-04-17 |
TW201420101A (zh) | 2014-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
MX2015004565A (es) | Metodo y dispositivo para conmutacion de camaras. | |
PH12017501079A1 (en) | 1,3-thiazol-2-yl substituted benzamides | |
CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
JP2015533163A5 (es) | ||
MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
JP2013520447A5 (es) | ||
BR112015012497A2 (pt) | combinações farmacêuticas | |
BR112016016098A2 (pt) | Compostos orgânicos | |
BR112015007095A8 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados | |
BR112013025368A8 (pt) | Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame | |
UY35748A (es) | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |